Leidos has been granted a patent for peptides with therapeutic applications including cancer inhibition, infectious disease treatment, vaccination response enhancement, sepsis treatment, and hair re-pigmentation. The patent claim specifies peptides with specific amino acid sequences. GlobalData’s report on Leidos gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Leidos Holdings Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Leidos, was a key innovation area identified from patents. Leidos's grant share as of May 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Peptides for therapeutic purposes

Source: United States Patent and Trademark Office (USPTO). Credit: Leidos Holdings Inc

A recently granted patent (Publication Number: US11987646B2) discloses a peptide with specific amino acid sequences, as well as an expression construct encoding this peptide. The patent further covers a pharmaceutical composition containing the peptide, a nucleic acid encoding the peptide, CAR-T cells expressing the peptide, or an oncolytic virus expressing the peptide, along with a pharmaceutically acceptable carrier. Additionally, the patent details the use of RNA as the nucleic acid, with specific modifications to enhance efficacy.

Moreover, the patent describes a method for inhibiting cancer progression, treating infectious diseases, enhancing vaccination responses, or treating sepsis by administering the pharmaceutical composition to individuals in need. The method allows for combination therapies, including cancer vaccines, CAR-T cell therapy, immune checkpoint inhibitors, cytokines, agonists of specific molecules, oncolytic viruses, and various therapeutic agents. Furthermore, the method extends to treating infectious diseases like malaria or hepatitis B, as well as using the peptide to address sepsis, showcasing the broad applicability of the patented technology in diverse medical conditions.

To know more about GlobalData’s detailed insights on Leidos, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.